NCT00879827View on ClinicalTrials.gov

Immunogenicity and Reactogenicity of GSK Bio DTPa-HBV-IPV and Hib Vaccines When Coadministered to Healthy Infants

PHASE3CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 30, 2000

Primary Completion Date

May 31, 2001

Study Completion Date

May 31, 2001

Conditions
DiphtheriaPoliomyelitisHepatitis BTetanusAcellular Pertussis
Interventions
BIOLOGICAL

Pediarix TM, Infanrix penta TM

The vaccines were administered according to a 3-dose schedule at 1.5, 3.5 and 6 months of age.

BIOLOGICAL

Hiberix TM

The vaccines were administered according to a 3-dose schedule at 1.5, 3.5 and 6 months of age.

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00879827 - Immunogenicity and Reactogenicity of GSK Bio DTPa-HBV-IPV and Hib Vaccines When Coadministered to Healthy Infants | Biotech Hunter | Biotech Hunter